【摘 要】
：
Background Autoimmune responses mediated by CD4+ T cells may contribute to the development of chronic obstructive pulmonary disease (COPD).
【机 构】
：
Department of Respiratory and Critical Care Medicine, the Affiliated Yinzhou Hospital, College of Me
【出 处】
：
2014中华医学会呼吸病学年会暨第十五次全国呼吸病学学术会议
论文部分内容阅读
Background Autoimmune responses mediated by CD4+ T cells may contribute to the development of chronic obstructive pulmonary disease (COPD).
其他文献
目的 探讨慢性阻塞性肺疾病稳定期及急性期患者血清V-谷氨酰转肽酶的变化及其与炎症的关系.方法 选取60例无肝脏及胆道疾病的慢性阻塞性肺疾病稳定期患者和60例急性期患者,测定患者血清γ-谷氨酰转肽酶活性与C反应蛋白、降钙素原及白介素6水平,并进行相关分析.
目的 探讨慢性阻塞性肺疾病(COPD)患者的急性加重与纤维蛋白原(FIB)、降钙素原(PCT)、C反应蛋白(CRP)的相关性.方法 纳入COPD患者,分为急性加重期和稳定期,急性加重期根据病情严重程度分为轻、中、重、极重度组,对比健康对照者,采集外周血,检测其中FIB、PCT、CRP水平.
目的 观察无创正压通气(NPPV)联合纳洛酮治疗慢性阻塞性肺疾病急性发作(AECOPD)合并肺性脑病的疗效.方法 将78例AECOPD合并肺性脑病的患者随机分成观察组和对照组两组,观察组39例,在综合治疗的基础上,采用NPPV联合纳洛酮治疗;对照组39例,除不用纳洛酮外,其他治疗同A组.
Objective Chronic obstructive pulmonary disease (COPD), a respiratory disorder caused largely by smoking and characterized by progressive, incompletely reversible airflow obstruction, is a leading cau
Background Although new chemotherapeutic drugs have been applied constantly, their efficacy for non-small cell lung cancer (NSCLC) is still not satisfying.
Background Oxidative stress plays an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD), and antioxidant therapy may have a potential effect in controlling chronic airw
Background In recent years, a new type of lung diagnosis device that uses the exhaled breath is being developed.It has long been known that breath contains clues to many diseases.One critical limitati
Backgrounds SP-D knockout (SP-D-/-) mice exhibit an increase in the number and size of airway macrophages, peribronchiolar inflammation, increases in metalloproteinase activity, and development of emp
Altered expression of miRNAs contributed to development and progression of non-small cell lung cancer (NSCLC), while transforming growth factor-beta (TGF-beta) promoted NSCLC cell epithelial-mesenchym
Background Accumulating evidence suggests that hypoglycaemic agents influence lung cancer risk in patients with diabetes.It remains to be fully elucidated whether conventional hypoglycaemic agents (me